Relmada Therapeutics, Inc. RLMD Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$58.88M-2.6% | -$57.39M-2.2% | -$56.17M+17.2% | -$67.81M+10.4% | -$75.71M+5.3% | ||
| $11.29M-18.8% | $13.91M-23.9% | $18.26M-19.2% | $22.6M-11.2% | $25.46M-15.6% | ||
| -$42.79M+6.6% | -$45.79M-14.5% | -$39.99M+19.9% | -$49.92M+12.1% | -$56.79M-9.7% | ||
| -$198.73M-313% | -$48.14M-220% | $40.14M-19.0% | $49.53M-12.9% | $56.86M+10.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Relmada Therapeutics, Inc. generate?
- Relmada Therapeutics, Inc. (RLMD) generated -$42.8M in operating cash flow over the trailing twelve months.
- What is Relmada Therapeutics, Inc.'s free cash flow?
- After $182.1M of capital expenditures, Relmada Therapeutics, Inc.'s free cash flow was -$209.9M over the trailing twelve months, down 116.5% year over year.
- Where does Relmada Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.